Pegaptanib sodium for the treatment of neovascular age-related macular degeneration

Bibliography

• GRAGOUDAS ES, ADAMIS AP, CUNNINGHAM ET Jr, FEINSOD M, GUYER DR: Pegaptanib for neovascular age-related macular degeneration. N Engl. J. Med. (2004) 351(27):2805–2816.
   PubMed Web of Science ®Google Scholar
• •The documents made publicly available by the FDA in preparation for regulatory approval of pegaptanib sodium; robust data describing the preclinical findings, clinical outcomes and safety data regarding the drug are also reviewed.
   Google Scholar
• EYETECH/PFIZER: Pegaptanib sodium injection in the treatment of neovascular age-related macular degeneration. Briefing Document for the FDA Dermatologic and Ophthalmic Drugs Advisory Committee. Rockville, Maryland, USA (2004).
   Google Scholar
• •The documents made publicly available by the FDA in preparation for regulatory approval of pegaptanib sodium; robust data describing the preclinical fmdings, clinical outcomes and safety data regarding the drug are also reviewed.
   Google Scholar
• EYETECH/PFIZER: Pegaptanib sodium injection (Macugen"). FDA Dermatologic and Ophthalmic Drugs Advisory Committee Meeting.August 27 2004. Food and Drug Administration, Rockville, Maryland, USA. (2004).
   Google Scholar
• ••This is the seminal paper describing the1-year clinical outcomes in patients receiving pegaptanib sodium for the treatment of neovascular AMD.
   Google Scholar
• Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch. Ophthalmol (1999) 117(10):1329–1345.
   Google Scholar
• BRESSLER NM: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch. Ophthalmol (2001) 119(2):198–207.
   PubMed Web of Science ®Google Scholar
• LEE P, WANG CC, ADAMIS AP: Ocular neovascularization: an epidemiologic review. Surv. Ophthalmol (1998) 43(3):245–269.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN DS, O'COLMAIN BJ, MUNOZ B et al.: Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol (2004) 122(4):564–572.
   Google Scholar
• FREUND KB, YANNUZZI LA, SORENSON JA: Age-related macular degeneration and choroidal neovascularization. Am. J. Ophthalmol. (1993) 115(6):786–791.
   PubMed Web of Science ®Google Scholar
• AGE-RELATED EYE DISEASE STUDY RESEARCH GROUP: Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology (2000) 107(12):2224–2232.
   Google Scholar
• AGE-RELATED EYE DISEASE STUDY RESEARCH GROUP: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and 0-carotene for age-related cataract and vision loss: AREDS report number 9. Arch. Ophthalmol (2001) 119(10):1439–1452.
   PubMed Web of Science ®Google Scholar
• YANNUZZI LA, NEGRAO S, IIDA T et al.: Retinal angiomatous proliferation in age-related macular degeneration. Retina (2001) 21(5):416–434.
   PubMed Web of Science ®Google Scholar
• Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch. Ophthalmol. (1991) 109(9):1220–1231.
   PubMed Web of Science ®Google Scholar
• Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch. Ophthalmol (1991) 109(9):1232–1241.
   PubMed Web of Science ®Google Scholar
• ADAMIS AP, SHIMA DT, YEO KT et al: Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. (1993) 193(2):631–638.
   PubMed Web of Science ®Google Scholar
• MILLER JW, ADAMIS AP, SHIMA DT et al.: Vascular endothelial growth factor/ vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol (1994) 145(3):574–584.
   PubMed Web of Science ®Google Scholar
• KVANTA A, ALGVERE PV, BERGLIN L, SEREGARD S: Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol Vis. Li. (1996) 37(9):1929–1934.
   PubMed Web of Science ®Google Scholar
• LOPEZ PF, SIPPY BD, LAMBERT HM, THACH AB, HINTON DR: Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest. Ophthalmol Vis. (1996) 37(5):855–868.
   PubMed Web of Science ®Google Scholar
• SHIMA DT, GOUGOS A, MILLER JW et al.: Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest. Ophthalmol Vis. Li. (1996) 37(7):1334–1340.
   PubMed Web of Science ®Google Scholar
• TOLENTINO MJ, MILLER JW, GRAGOUDAS ES et al: Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch. Ophthalmol (1996) 114(8):964–970.
   PubMed Web of Science ®Google Scholar
• TOLENTINO MJ, MILLER JW, GRAGOUDAS ES et al.: Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology (1996) 103(11):1820–1828.
   PubMed Web of Science ®Google Scholar
• TOLENTINO MJ, ADAMIS AP: Angiogenic factors in the development of diabetic iris neovascularization and retinopathy. Int. Ophthalmol Clin. (1998) 38(1):77–94.
   PubMedGoogle Scholar
• HOFMAN P, BLAAUWGEERS HG, TOLENTINO MJ et al.: VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A. Curr. Eye Res. (2000) 21(2):637–645.
   Google Scholar
• THE EYETECH STUDY GROUP: Preclinical and Phase IA clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina (2002) 22(2):143–152.
   PubMed Web of Science ®Google Scholar
• THE EYETECH STUDY GROUP: Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology (2003) 110(5):979–986.
   PubMed Web of Science ®Google Scholar
• KRZYSTOLIK MG, AFSHARI MA, ADAMIS AP et al: Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol (2002) 120(3):338–346.
   PubMed Web of Science ®Google Scholar
• CARRASQUILLO KG, RICKER JA, RIGAS IK et al: Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest. Ophthalmol. Vis. Sri. (2003) 44(1):290–299.
   PubMed Web of Science ®Google Scholar
• NIMJEE SM, RUSCONI CP, SULLENGER BA: APTAMERS: an emerging class of therapeutics. Ann. Rev Med (2005) 56:555–583.
   PubMed Web of Science ®Google Scholar
• TUERK C, GOLD L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 249(4968):505–510.
   PubMed Web of Science ®Google Scholar
• FERRARA N, HILLAN KJ, GERBER HP, NOVOTNY W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev Drug Discov. (2004) 3(5):391–400.
   PubMed Web of Science ®Google Scholar
• USUI T, ISHIDA S, YAMASHIRO K et al: VEGF164 (165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest. Ophthalmol Vis. (2004) 45(2):368–374.
   PubMed Web of Science ®Google Scholar
• ISHIDA S, USUI T, YAMASHIRO K et al: VEGF164-mediated inflammation is 681 required for pathological, but not physiological, ischemia-induced retinal neovascularization. J. Exp. Med. (2003) 198(3):483–489.
   PubMed Web of Science ®Google Scholar
• PASKOWITZ DM, NUNE G, YASUMURA D et al.: BDNF reduces the retinal toxicity of verteporfin photodynamic therapy. Invest. Ophthahnol. Vis. Sci. (2004) 45(10:4190–4196.
   PubMedGoogle Scholar
• MILES AA, MILES EM: Vascular reactionsto histamine, histamine liberators or leukotoxins in the skin of the guinea pig. Physiol. (1952) 118:228–257.
   Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl. Med. (2004) 350(23):2335–2342.
   PubMed Web of Science ®Google Scholar